Predict your next investment

See what CB Insights has to offer

Investments

1

About Lewis Katz

Lewis Katz Headquarters Location

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Lewis Katz News

Temple researcher receives NIH award to study the link between HIV, substance use and heart disease

Jun 15, 2022

With prompt diagnosis and the right treatment, people with HIV can live long, healthy lives. In recent years, however, gains in survival among people with HIV have exposed a new concern – an increase in the incidence of early-onset cardiovascular disease associated with long-term HIV. The reason why cardiovascular disease is likely to develop a full decade earlier in people with HIV than in people without HIV is unclear. But now, with the support of a National Institute on Drug Abuse Avenir Award, part of the National Institutes of Health (NIH) Director's New Innovator (DP2) Award Program, researchers at the Lewis Katz School of Medicine at Temple University hope to gain new insight into the relationship between HIV and heart disease, as well as the effect of substance use on this relationship. The DP2 award – a first for Temple – is highly competitive, supporting transformative research in high-priority areas designated by the NIH. The funding, $2,377,500 spread over four years, will support studies led by Allison M. Andrews, PhD, Assistant Professor in the Department of Pathology and Laboratory Medicine at the Lewis Katz School of Medicine at Temple University. The research will focus specifically on elucidating the effects of HIV and cocaine use on the bone-marrow blood barrier, a physiological boundary that prevents immature blood cells from escaping the bone marrow. We are particularly interested in studying changes in the bone marrow vasculature, microenvironment, and stem cell niche that result from HIV and drugs, such as cocaine." Dr. Allison M. Andrews, PhD, Assistant Professor, Department of Pathology and Laboratory Medicine, Lewis Katz School of Medicine, Temple University Related Stories Early-onset cardiovascular disease in people with HIV is associated with increased infiltration of immune cells into the blood vessel wall to form unstable plaques. These immune cells mature from hematopoietic stem cells (HSCs) in the bone marrow niche. It is perhaps no coincidence that the bone marrow also happens to be a reservoir of HIV. Dr. Andrews and others suspect that HIV somehow alters the local marrow microenvironment and HSC development to ultimately facilitate differentiation of HSCs into activated immune cells. They hypothesize that cocaine, which exacerbates HIV pathology, may amplify the effects of HIV on the bone marrow, or it may enable HSC differentiation via an entirely different mechanism. Dr. Andrews plans to investigate these ideas through the proposed development of a human bone marrow chip, in which human bone marrow stem cells are embedded in a gel matrix that essentially mimics the 3D nature of bone marrow tissue. Each chip is about the size of a USB flash drive. Using microCT and other advanced imaging techniques, Dr. Andrews and colleagues also plan to map the 3D architecture of the bone marrow vasculature of HIV-infected mice. "Through these studies, we aim to create a new human 3D tissue-engineered model of the bone marrow vasculature for the study of HIV pathogenesis," Dr. Andrews added. "The technology is also a promising tool for predictive modeling that could translate clinically into the development of novel strategies for the care of people with HIV who face cardiovascular disease." Source:

Lewis Katz Investments

1 Investments

Lewis Katz has made 1 investments. Their latest investment was in Twill as part of their Series A on February 2, 2013.

CBI Logo

Lewis Katz Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

2/7/2013

Series A

Twill

$1.82M

Yes

1

Date

2/7/2013

Round

Series A

Company

Twill

Amount

$1.82M

New?

Yes

Co-Investors

Sources

1

Lewis Katz Acquisitions

2 Acquisitions

Lewis Katz acquired 2 companies. Their latest acquisition was The Philadelphia Inquirer on May 27, 2014.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

5/27/2014

$99M

Acquired

1

4/4/2012

Subscribe to see more

$99M

Subscribe to see more

10

Date

5/27/2014

4/4/2012

Investment Stage

Companies

Subscribe to see more

Valuation

$99M

$99M

Total Funding

Note

Acquired

Subscribe to see more

Sources

1

10

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.